# Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL

> **NCT00185445** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 62 (actual)

## Conditions studied

- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** Fludarabine Phosphate (Fludara)

## Key facts

- **NCT ID:** NCT00185445
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00185445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00185445, "Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00185445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*